<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28488960</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2385-2070</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Blood transfusion = Trasfusione del sangue</Title><ISOAbbreviation>Blood Transfus</ISOAbbreviation></Journal><ArticleTitle>Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.</ArticleTitle><Pagination><StartPage>512</StartPage><EndPage>521</EndPage><MedlinePgn>512-521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2450/2017.0344-16</ELocationID><Abstract><AbstractText>Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusion-transmitted infection. Without efficient donor screening/viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol<sup>&#xae;</sup> Pathogen Reduction Technology, INTERCEPT<sup>&#xae;</sup>, and THERAFLEX<sup>&#xae;</sup>. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2<sup>nd</sup>-generation of the INTERCEPT<sup>&#xae;</sup> S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drew</LastName><ForeName>Victor J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barro</LastName><ForeName>Lassina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center of Blood Transfusion, Ouagadougou, Burkina Faso, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seghatchian</LastName><ForeName>Jerard</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>International Consultancy in Blood Components Quality Improvement/Safety, Audit/Inspection and DDR Strategy, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnouf</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Blood Transfus</MedlineTA><NlmUniqueID>101237479</NlmUniqueID><ISSNLinking>1723-2007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001769" MajorTopicYN="N">Blood</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058731" MajorTopicYN="N">Blood Safety</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004203" MajorTopicYN="N">Disinfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010961" MajorTopicYN="N">Plasmodium</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013587" MajorTopicYN="N">Syphilis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014210" MajorTopicYN="N">Treponema pallidum</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The Authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28488960</ArticleId><ArticleId IdType="pmc">PMC5649960</ArticleId><ArticleId IdType="doi">10.2450/2017.0344-16</ArticleId><ArticleId IdType="pii">2017.0344-16</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. 10 Facts on Blood Transfusion. 2016.  [Accessed on 05/04/2017].  Available from:  http://www.who.int/features/factfiles/blood_transfusion/en/</Citation></Reference><Reference><Citation>Picker SM. Pathogen Reduction Technologies: the best solution for safer blood? J Blood Disord Transfus. 2013;3:133.</Citation></Reference><Reference><Citation>Lozano M, Cid J. Platelet concentrates: Balancing between efficacy and safety? Presse Med. 2016;45:e289&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">27476010</ArticleId></ArticleIdList></Reference><Reference><Citation>Freimanis G, Sedegah M, Owusu-Ofori S, et al. Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system. Transfusion. 2013;53:1429&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23113534</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Annex 4: WHO guidelines on good manufacturing practices for blood establishments. 2011.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/bloodproducts/publications/GMP_Bloodestablishments.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Annex 4: WHO recommendations for the production, control and regulation of human plasma for fractionation. 2005.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/biologicals/publications/ECBS2005Annex4HumanPlasmaFractionation.pdf.</Citation></Reference><Reference><Citation>Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22:839&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322797</ArticleId><ArticleId IdType="pubmed">27400264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanki PJ, Hamel DJ, Sankal&#xe9; J-L, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999;179:68&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841824</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhingra N. Making safe blood available in Africa. 2006.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/bloodsafety/makingsafebloodavailableinafricastatement.pdf.</Citation></Reference><Reference><Citation>Bruisten S, Van Gemen B, Koppelman M, et al. Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplification assays. AIDS research and human retroviruses. 1993;9:259&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8471317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Stromberg R, Heitman J, et al. Distribution of HIV type 1 (HIV-1) in blood components: detection and significance of high levels of HIV-1 associated with platelets. Transfusion. 1998;38:580&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9661692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott J, Stevens G, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22273662</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Fact sheet: Hepatitis B. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/mediacentre/factsheets/fs204/en/</Citation></Reference><Reference><Citation>Seo DH, Whang DH, Song EY, et al. Occult hepatitis B virus infection and blood transfusion. World J Hepatol. 2015;7:600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4381183</ArticleId><ArticleId IdType="pubmed">25848484</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Fact sheet: Blood safety and availability. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/mediacentre/factsheets/fs279/en/</Citation></Reference><Reference><Citation>Australian Red Cross Blood Service. 2015 Surveillance Report: Transfusion-transmissible infections in Australia. 2015.  [Accessed on 05/04/2017].  Available at:  https://kirby.unsw.edu.au/sites/default/files/hiv/resources/tti2015_20160226.pdf.</Citation></Reference><Reference><Citation>Seed C, Maloney R, Kiely P, et al. Infectivity of blood components from donors with occult hepatitis B infection-results from an Australian lookback programme. Vox sanguinis. 2015;108:113&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">25234417</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. Journal of General Virology. 2004;85:3173&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483230</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno M, P&#xe9;rez-Alvarez R, Rodrigo L, et al. Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response. Journal of viral hepatitis. 2006;13:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23172780</ArticleId></ArticleIdList></Reference><Reference><Citation>Thong VD, Akkarathamrongsin S, Poovorawan K, et al. Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. WJG. 2014;20:2927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961978</ArticleId><ArticleId IdType="pubmed">24659883</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao D, Abe K, Nguyen M. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Alimentary pharmacology &amp; therapeutics. 2011;34:286&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">21623850</ArticleId></ArticleIdList></Reference><Reference><Citation>Well E, First F, it Out W, et al. Study identifies hepatitis C virus genotype 1 as the most prevalent worldwide. Nursing Standard. 2014;50:17.</Citation></Reference><Reference><Citation>Centers for Dis ease Control and Prevention. Hepatitis C FAQs for the public. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.cdc.gov/hepatitis/hcv/cfaq.htm.</Citation></Reference><Reference><Citation>Padovani JL, Corvino SM, Drexler JF, et al. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus. Revista da Sociedade Brasileira de Medicina Tropical. 2013;46:154&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23559343</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer A, Abu Madi M, Shebl F, et al. Platelets as a possible reservoir of HCV and predictor of response to treatment. J Virol Antivir Res. 2016;5:3.</Citation></Reference><Reference><Citation>Schmidt WN, Wu P, Han J-Q, et al. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. J Infect Dis. 1997;176:20&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9207345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11:1188&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110646</ArticleId><ArticleId IdType="pubmed">21401874</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios M, Daniel S, Chancey C, et al. West Nile virus adheres to human red blood cells in whole blood. Clin Infect Dis. 2007;45:181&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17578776</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">16983682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358:261&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498211</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington T, Kuehnert MJ, Kamel H, et al. West Nile virus infection transmitted by blood transfusion. Transfusion. 2003;43:1018&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12869105</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a G, Gonz&#xe1;lez N, P&#xe9;rez AB, et al. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis. 2011;15:e38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21112804</ArticleId></ArticleIdList></Reference><Reference><Citation>Endy TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol. 2002;156:40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, He R, Patarapotikul J, et al. Antibody-enhanced binding of dengue-2 virus to human platelets. Virology. 1995;213:254&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7483271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W-K, Sung T-L, Tsai Y-C, et al. Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol. 2002;40:4472&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154639</ArticleId><ArticleId IdType="pubmed">12454138</ArticleId></ArticleIdList></Reference><Reference><Citation>Liumbruno GM, Calteri D, Petropulacos K, et al. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus. 2008;6:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626913</ArticleId><ArticleId IdType="pubmed">19112735</ArticleId></ArticleIdList></Reference><Reference><Citation>Parola P, De Lamballerie X, Jourdan J, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis. 2006;12:1493&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290960</ArticleId><ArticleId IdType="pubmed">17176562</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno G, Perno CF, Tiede A, et al. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev. 2016;30:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115716</ArticleId><ArticleId IdType="pubmed">26381318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal A, Mittal S, Bharathi JM, et al. Uveitis during outbreak of Chikungunya fever. Ophthalmology. 2007;114:1798.</Citation><ArticleIdList><ArticleId IdType="pubmed">17822999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal A, Mittal S, Bharati MJ, et al. Optic neuritis associated with chikungunya virus infection in South India. Arch Ophthalmol. 2007;125:1381&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. New Engl J Med. 2016;374:951&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26862926</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Fact sheet: Zika. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/mediacentre/factsheets/zika/en/</Citation></Reference><Reference><Citation>Brasil P, Pereira J, Jose P, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. New Engl J Med. 2016;375:2321&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5323261</ArticleId><ArticleId IdType="pubmed">26943629</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsica F. Zika virus transmission from French Polynesia to Brazil. Emerg Infect Dis. 2015;21:1887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593458</ArticleId><ArticleId IdType="pubmed">26403318</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Dis ease Control and Prevention. Zika and blood transfusion. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.cdc.gov/zika/transmission/blood-transfusion.html.</Citation></Reference><Reference><Citation>Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. New Engl J Med. 2016;375:1101&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27532622</ArticleId></ArticleIdList></Reference><Reference><Citation>Food &amp; Drug Administration. FDA advises testing for Zika virus in all donated blood and blood components in the US. 2016.  [Accessed on 05/04/2017].  Available at:  https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518218.htm.</Citation></Reference><Reference><Citation>Cohen SE, Klausner JD, Engelman J, et al. Syphilis in the modern era: an update for physicians. Infect Dis Clin North Am. 2013;27:705&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">24275265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion. 2001;41:1069&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen V, Su J, Torrone E, et al. Increase in incidence of congenital syphilis - United States, 2012&#x2013;2014. MMWR Morb Mortal Wkly Rep. 2015;64:1241&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26562206</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis M, De Luca C, Mappa I, et al. Syphilis infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol. 2012;2012:430585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398589</ArticleId><ArticleId IdType="pubmed">22829747</ArticleId></ArticleIdList></Reference><Reference><Citation>Owusu-Ofori AK, Parry CM, Bates I. Transfusion-transmitted syphilis in teaching hospital, Ghana. Emerg Infect Dis. 2011;17:2080&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310592</ArticleId><ArticleId IdType="pubmed">22099108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisseye C, Sanou M, Nagalo BM, et al. Epidemiology of syphilis in regional blood transfusion centres in Burkina Faso, West Africa. Pan Afr Med J. 2013;16:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976651</ArticleId><ArticleId IdType="pubmed">24711869</ArticleId></ArticleIdList></Reference><Reference><Citation>Angchaisuksiri P. Coagulopathy in malaria. Thromb Res. 2014;133:5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24099998</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Fact sheet: Malaria. 2016.  [Accessed on 05/04/2017].  Available at:  http://www.who.int/mediacentre/factsheets/fs094/en/</Citation></Reference><Reference><Citation>Tusting LS, Bousema T, Smith DL, et al. Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol. 2014;84:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847140</ArticleId><ArticleId IdType="pubmed">24480314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchen A, Chiodini P. Malaria and blood transfusion. Vox Sang. 2006;90:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16430664</ArticleId></ArticleIdList></Reference><Reference><Citation>del Prado GRL, Garc&#xed;a CH, Cea LM, et al. Malaria in developing countries. J Infect Develop Count. 2014;8:1&#x2013;4.</Citation></Reference><Reference><Citation>Kleinschmidt I, Schwabe C, Benavente L, et al. Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg. 2009;80:882&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748782</ArticleId><ArticleId IdType="pubmed">19478243</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner D, Daily J, Baron EL. Pathogenesis of malaria. UpToDate. 2012.  [Accessed on 05/04/2017].  Available at:  www.uptodate.com.</Citation></Reference><Reference><Citation>Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion. 2015;55:2983&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169855</ArticleId><ArticleId IdType="pubmed">26303806</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin P, Mackenzie J, Llewelyn C, et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 2016;110:310&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26709606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neisser-Svae A, Seghatchian J. The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product. Transfus Aphs Sci. 2015;52:237&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25748229</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Dis ease Control and Prevention. Diseases and organisms: blood safety. 2013.  [Accessed on 05/04/2017].  Available at:  http://www.cdc.gov/bloodsafety/bbp/diseases_organisms.html.</Citation></Reference><Reference><Citation>Chatterjee K, Zaman S, Chaurasia R, et al. Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis: a pilot study from India. Asian Journal of Transfusion Science. 2016;10:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993081</ArticleId><ArticleId IdType="pubmed">27605849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoad VC, Speers DJ, Keller AJ, et al. First reported case of transfusion-transmitted Ross River virus infection. Med J Aust. 2015;202:267&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">25758699</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Brit J Haematol. 2012;159:135&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161751</ArticleId><ArticleId IdType="pubmed">22924410</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21:101&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125842</ArticleId><ArticleId IdType="pubmed">17397761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Yao M. Pathogen inactivation plays an irreplaceable role in safeguarding the safety of blood transfusion. J Antivir Antiretrovir. 2016;8:LXXIII&#x2013;LXXIV.</Citation></Reference><Reference><Citation>Mundt JM, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol. 2014;90:957&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277684</ArticleId><ArticleId IdType="pubmed">25041351</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1310064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou M-L, Burnouf T, Chang S-P, et al. TnBP/Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PloS one. 2015;10:e0117800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320006</ArticleId><ArticleId IdType="pubmed">25658612</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Ekiaby M, Sayed M, Caron C, et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transf Med. 2010;20:48&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19778318</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnouf T, Chou ML, Cheng LH, et al. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate. Vox Sang. 2013;104:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22758375</ArticleId></ArticleIdList></Reference><Reference><Citation>Prowse C. Component pathogen inactivation: a critical review. Vox Sang. 2013;104:183&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou ML, Wu YW, Su CY, et al. Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang. 2012;102:277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22092109</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh GM, Shih AW, Solh Z, et al. Blood-Borne pathogens: a Canadian blood services centre for innovation symposium. Transfus Med Rev. 2016;30:53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126603</ArticleId><ArticleId IdType="pubmed">26962008</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother. 2014;41:309&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4164100</ArticleId><ArticleId IdType="pubmed">25254027</ArticleId></ArticleIdList></Reference><Reference><Citation>Salunkhe V, van der Meer PF, de Korte D, et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Aph Sci. 2015;52:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25620756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014;28:235&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">25192602</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiglia S, Mareschi K, Labanca L, et al. Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in good manufacturing practice conditions. Cytotherapy. 2014;16:750&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185570</ArticleId><ArticleId IdType="pubmed">24529555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tormey CA, Santhanakrishnan M, Smith NH, et al. Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion. 2016;56:863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26643781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto JT, Zempleni J. Riboflavin. Adv Nutr. 2016;7:973&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5015041</ArticleId><ArticleId IdType="pubmed">27633112</ArticleId></ArticleIdList></Reference><Reference><Citation>Food &amp; Drug Administration. Select Committee on GRAS Substances (SCOGS) Opinion: Riboflavin, Riboflavin-5&#x2032;-phosphate. 2015.  [Accessed on 05/04/2017].  Available at:  https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm261091.htm.</Citation></Reference><Reference><Citation>Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion. 2009;49:1205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">19320867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobral PM, Barros AEdL, Gomes AMAS, et al. Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids. Rev Bras Hematol Hemoter. 2012;34:231&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459627</ArticleId><ArticleId IdType="pubmed">23049426</ArticleId></ArticleIdList></Reference><Reference><Citation>Allain J-P, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet. 2016;387:1753&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">27116282</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghatchian J. Multilayer-strategy to enhance optimal safety of the blood supply: the role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: moderator views. Transfus Apher Sci. 2015;52:233&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25748230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltshire M, Meli A, Schott M, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med. 2016;26:208&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27006102</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa G, Seghatchian J. Highlights of PBTI coimbra conference on PRT of plasma &amp; current opinions on pathogen reduction treatment of blood components. Transfus Apher Sci. 2015;52:228&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">25770045</ArticleId></ArticleIdList></Reference><Reference><Citation>AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion. 2002;42:146&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896327</ArticleId></ArticleIdList></Reference><Reference><Citation>Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci. 2008;39:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18602343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon SY. Pathogen reduction technology - is it time? ISBT Sci Ser. 2016;11:117&#x2013;22.</Citation></Reference><Reference><Citation>Nkohkwo Aa, Agbor G, Asongalem E, et al. Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion. Afr J Lab Med. 2016;5:a363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5436399</ArticleId><ArticleId IdType="pubmed">28879109</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 2005;45:1739&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271099</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks D, Faddy H, Johnson L. Pathogen reduction technologies. ISBT Sci Ser. 2014;9:44&#x2013;50.</Citation></Reference><Reference><Citation>Seghatchian J, Putter JS. Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci. 2013;49:357&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23962395</ArticleId></ArticleIdList></Reference><Reference><Citation>Garraud O, Cognasse F, Tissot J-D, et al. Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfus. 2016;14:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781777</ArticleId><ArticleId IdType="pubmed">26674828</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>